Fig. 2From: Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studiesFit plot of cross-reactive insulin antibody percent specific binding assays in (a) INSTRIDE 1 and (b) INSTRIDE 2Back to article page